NR 715 Week 3 Concept Analysis Example

Clinical Inertia in Heart Failure Medication Titration: A Walker and Avant Concept Analysis With Attributes Two Readers Would Apply the Same Way

Student Name

College of Nursing, Chamberlain University

NR 715: Scientific Underpinnings

Instructor Name

Month Day, Year

Clinical Inertia in Heart Failure Medication Titration: A Walker and Avant Concept Analysis With Attributes Two Readers Would Apply the Same Way

Aim

The aim is to define clinical inertia precisely enough that two clinicians reviewing the same heart failure visit record would agree on whether it is present. The analysis follows the eight steps described by Walker and Avant (2019), compressed where a step needs less space, and it is written for one purpose: to turn the 571 unexplained no-change visits counted in the problem statement into a category with edges.

Uses of the Term

The term entered medicine through a 2001 paper that defined clinical inertia as the failure of health care providers to initiate or intensify therapy when indicated, and which attributed it to overestimating the care already provided, to soft reasons for not acting and to practice organization that does not aim at treatment goals (Phillips et al., 2001). Since then it has been used most heavily in diabetes care, where reviews describe long delays before treatment is intensified and assign them jointly to the clinician, the patient and the health system (Khunti et al., 2018; Reach et al., 2017). Some writers prefer therapeutic inertia, to include patient and system contributions; others keep clinical inertia for the clinician's decision. In physics, inertia is a body's tendency to continue in its current state unless a force acts on it, a sense that carries into the clinical term: therapy stays as it is unless something moves it. In organizational writing, inertia describes a firm's failure to change despite signals that it should. Across these uses, the common core is a gap between a signal that change is warranted and the absence of change.

Defining Attributes

Four attributes are proposed. Each must be present for a visit to count as clinical inertia.

First, an indication: a treatment goal exists, and at the encounter the patient is measurably short of it. In HFrEF, this means the patient is below the target dose of at least one recommended drug class.

Second, availability: the information showing the gap, the current doses and the values needed to judge safety such as blood pressure, potassium and kidney function, is in front of the clinician at the encounter.

Third, no change: no drug is started and no dose is increased at that encounter.

Fourth, no sound reason: neither the record nor the circumstances show a clinically defensible reason for leaving therapy as it is, such as symptomatic low blood pressure, a pending procedure or the patient's informed request to wait.

Applied to a record, each attribute can be answered yes or no. Two reviewers who read the same note and laboratory panel should give the same four answers, which is the test this analysis is written to pass.

Model Case

A patient, 68, with an ejection fraction of 30%, attends a twenty-minute follow-up. The record shows a beta-blocker at half the target dose and no mineralocorticoid receptor antagonist. The blood pressure in clinic is 124/76 mm Hg, and labs drawn five days earlier show a potassium of 4.3 mmol/L and an estimated glomerular filtration rate of 58 mL/min/1.73 m2. The clinician reviews breathlessness and weight, notes that the patient feels stable, renews the existing prescriptions and books a return in three months. Nothing in the note explains why the doses were left. Each of the four attributes is present.

Borderline Case

A patient, 74, with an ejection fraction of 35%, attends a follow-up on a lisinopril dose below target. The pressure is 132/80 mm Hg, but the last potassium and kidney function on file are four months old. The clinician orders new labs, makes no change and plans to call with a decision. The labs return two days later and are normal, but no call is made. At the visit itself, the second attribute is absent: the information needed to judge safety was not in front of the clinician. The case sits on the boundary between inertia and system latency, and it shows why availability is an attribute rather than an assumption. Its follow-up call, not the visit, is where inertia may have occurred.

Contrary Case

A patient, 61, with an ejection fraction of 25%, attends on a beta-blocker below target and no sodium-glucose cotransporter 2 inhibitor. The pressure is 118/72 mm Hg and recent labs are within range. The clinician starts the new drug, explains what to expect and books a nurse call at two weeks. There is no inertia here: the third attribute, no change, is absent, and so is the fourth.

A Related Case

A patient, 79, meets the indication, has current labs and leaves unchanged, but the note records that the patient is moving to a daughter's home next week and asked to delay any change until settled. Only the fourth attribute is missing. This is deferral with a reason, a related concept that the clinic counts separately; including it in inertia would treat a shared decision as a failure.

Antecedents

Antecedents are events that must occur before the concept can: a treatment target defined in guidance the clinician accepts, a measured value showing the patient short of it and an encounter at which a change could be made. Conditions that make inertia more likely, short appointments, competing problems on the agenda, uncertainty about kidney function or low blood pressure and the absence of a protocol for titration between visits, are contributing conditions rather than antecedents, because inertia can occur without any of them.

Consequences

The direct consequence is time spent below target dose until the next opportunity, which in this clinic means a median wait of 91 days. Downstream consequences in heart failure include a lost share of the reduction in hospitalization that the drug classes provide in trials, more unplanned visits and, for the clinic, a backlog as post-discharge visits displace routine ones. For the clinician, repeated inertia can normalize the current dose as the right dose, which makes the next visit's inertia more likely.

Empirical Referents

The concept is measured at the visit. A visit is classed as clinical inertia when the record shows a dose below target for at least one class, labs no older than 30 days and an in-clinic pressure, no new drug or dose increase and no documented reason in either the structured field or the free-text plan. The clinic's structured count of 571 visits measures the first three attributes well and the fourth imperfectly, which is why a chart review of a sample is part of the measure.

Definition

Clinical inertia, in heart failure titration, is a visit at which a patient short of a target dose, with the information needed to judge safety available, leaves with no drug started or increased and no sound reason recorded or evident.

References

Khunti, K., Gomes, M. B., Pocock, S., Shestakova, M. V., Pintat, S., Fenici, P., Hammar, N., & Medina, J. (2018). Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review. Diabetes, Obesity and Metabolism, 20(2), 427-437. https://doi.org/10.1111/dom.13088

Phillips, L. S., Branch, W. T., Cook, C. B., Doyle, J. P., El-Kebbi, I. M., Gallina, D. L., Miller, C. D., Ziemer, D. C., & Barnes, C. S. (2001). Clinical inertia. Annals of Internal Medicine, 135(9), 825-834. https://doi.org/10.7326/0003-4819-135-9-200111060-00012

Reach, G., Pechtner, V., Gentilella, R., Corcos, A., & Ceriello, A. (2017). Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes & Metabolism, 43(6), 501-511. https://doi.org/10.1016/j.diabet.2017.06.003

Walker, L. O., & Avant, K. C. (2019). Strategies for theory construction in nursing (6th ed.). Pearson.